Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.

J Clin Oncol · 2023 · PMC9870233 · PMID 35960908

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

21 - 24 The preliminary OS analysis (minimum follow-up of 9.1 months) of ELOQUENT-3 showed a trend toward improved OS with EPd versus Pd, although the data were still immature. 20 A subsequent unplanned interim analysis (minimum follow-up of 18.3 months) continued to show an OS trend in favor of EPd. 25 Here, we report the final OS analysis, with a minimum follow-up of 45 months from ELOQUENT-3.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.